Table 1. Antimicrobial susceptibility profiles of linezolid-resistant clinical strains.
| Staphylococcal isolates | MIC (in µg/ml)* | ||||||||||||||||
| LZD | CHL | CLI | FFC | TIA | VM1 | Q-D | OXA | FOX | LEV | ERY | RIF | TGC | SXT | GEN | VAN | TEC | |
| S. haemolyticus 09D279 | 8 | 256 | 32 | 256 | 256 | 32 | 2 | ≥512 | 256 | 16 | 0.25 | 0.008 | 0.125 | 64 | 8 | 0.5 | 4 |
| S. cohnii 09D253 | 32 | 128 | ≥512 | 256 | 128 | >128 | 4 | 1 | 8 | 8 | ≥512 | 0.016 | 0.125 | 0.125 | 1 | 0.5 | 2 |
| S. cohnii 09D363 | 32 | 128 | ≥512 | 256 | 128 | 128 | 4 | 0.5 | 8 | 8 | ≥512 | 0.008 | 0.125 | 0.125 | 2 | 0.5 | 2 |
| S. cohnii NDM113 | 32 | 128 | 256 | 256 | 128 | 128 | 8 | 128 | 32 | 8 | 256 | 0.008 | 0.25 | 0.125 | 32 | 0.5 | 1 |
| S. aureus RN4220 | 2 | 8 | 0.125 | 1 | 0.5 | 0.5 | 0.25 | 0.125 | 1 | 0.25 | 0.125 | 0.008 | 0.125 | 0.125 | 0.125 | 2 | 0.5 |
| S. aureus RN4220 + pSS-02-like (09D279) | 8 | >256 | >256 | 128 | 64 | 4 | 2 | 0.125 | 1 | 0.25 | 0.125 | 0.008 | 0.125 | 0.125 | 0.125 | 2 | 0.5 |
| S. aureus RN4220 + pSS-02-like (09D253) | 8 | >256 | >256 | 128 | 64 | 4 | 2 | 0.125 | 1 | 0.25 | 0.125 | 0.008 | 0.125 | 0.125 | 0.125 | 2 | 0.5 |
| S. aureus RN4220 + pSS-02-like (09D363) | 8 | >256 | >256 | 128 | 64 | 4 | 1 | 0.125 | 1 | 0.25 | 0.25 | 0.008 | 0.125 | 0.125 | 0.125 | 2 | 0.5 |
| S. aureus RN4220 + pSS-02-like (NDM113) | 8 | >256 | >256 | 128 | 64 | 4 | 2 | 0.125 | 1 | 0.25 | 0.125 | 0.008 | 0.125 | 0.125 | 0.25 | 2 | 0.5 |
| S. aureus RN4220 + pSS-02 | 8 | >256 | >256 | 256 | 64 | 4 | 2 | 0.12 | 1 | 0.25 | 0.125 | 0.016 | 0.125 | 0.125 | 0.25 | 2 | 0.5 |
*
LZD, linezolid; CHL, chloramphenicol, CLI, clindamycin; FFC, florfenicol; TIA, tiamulin; VM1, virginiamycin M1; Q-D, quinupristin/dalfopristin; OXA, oxacillin; FOX, cefoxitin; LEV, levofloxacin; ERY, erythromycin; RIF, rifampicin; TGC, tigecycline; SXT, sulfamethoxazole-trimethoprim; GEN, gentamicin; VAN, vancomycin; TEC, teicoplanin.